Shelley Shapiro, MD
Pulmonary Disease · Los Angeles, CANPI 1760402846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. United Therapeutics Corporation accounts for 72.6% of it on its own, with 9 other manufacturers making up the rest.
Across 33 payments — averaging $56.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$1K
- Actelion Pharmaceuticals US, Inc.$314
- Biotronik Inc.$40
- Bayer$33
- Merck$26
- Abiomed$22
- plus $76 from 4 others
Across 107 payments — averaging $9738.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$519K
- Medtronic$388K
- Sumitomo Pharma America, Inc.$119K
- Janssen Research & Development, LLC$12K
- Actelion Pharmaceuticals US, Inc.$2K
- Novartis$839
What the payments were for
- Food & beverage$1,73693%
- Education$1257%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 20 | $1,350 |
| Actelion Pharmaceuticals US, Inc. | 5 | $314 |
| Biotronik Inc. | 1 | $40 |
| Bayer | 1 | $33 |
| Merck | 1 | $26 |
| Abiomed | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,861 in reported general payments places this provider in the 55th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 147 | $3,761,173 |
| OpsumitMacitentan | 173 | $2,131,535 |
| AdempasRiociguat | 95 | $1,283,051 |
| WinrevairSotatercept-Csrk | 76 | $1,161,369 |
| Ambrisentan | 253 | $770,773 |
| LetairisAmbrisentan | 49 | $628,728 |
| AdcircaTadalafil | 107 | $543,205 |
| UptraviSelexipag | 23 | $489,778 |
| Tyvaso Refill KitTreprostinil/Neb Accessories | 16 | $324,369 |
| Tadalafil | 277 | $290,268 |
| RemodulinTreprostinil Sodium | 17 | $107,001 |
| Orenitram ErTreprostinil Diolamine | 21 | $105,702 |
| Potassium Chloride | 54 | $2,593 |
| Digoxin | 62 | $1,621 |
| Furosemide | 62 | $733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $314 | $2,621,313196 claims |
| BayerAdempas | $33 | $1,283,05195 claims |
| MerckWinrevair | $26 | $1,161,36976 claims |
| United Therapeutics CorporationAdcirca, Remodulin | $1,350 | $650,206124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$1.3M
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
- Igor BarjaktarevicLos Angeles$337K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Donald TashkinLos Angeles$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.